488713-71-9

Basic information

• Product Name: 2-[5'-aminomethyl-5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-biphenyl-3-yl]-succinic acid
• Synonyms: 2-[5'-aminomethyl-5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-biphenyl-3-yl]-succinic acid
• CAS NO: 488713-71-9
• Molecular Weight: 489.488
• Mol File: 488713-71-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-[5'-aminomethyl-5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-biphenyl-3-yl]-succinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[5'-aminomethyl-5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-biphenyl-3-yl]-succinic acid(488713-71-9)
• EPA Substance Registry System: 2-[5'-aminomethyl-5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-biphenyl-3-yl]-succinic acid(488713-71-9)

Safety Data

• Hazardous Substances Data: 488713-71-9(Hazardous Substances Data)

Upstream product

• 488713-52-6 2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-5'-cyano-6,2'-dihydroxy-biphenyl-3-yl]-succinic acid 
• 22248-26-6 2-(4-methoxy-phenyl)-succinic acid dimethyl ester 
• 136705-25-4 (4-hydroxy-phenyl)-succinic acid dimethyl ester 
• 23053-35-2 2-(4'-hydroxyphenyl)butane-1,4-dioic acid 
• 696-62-8 para-iodoanisole 
• 883993-75-7 2-[5'-cyano-5-formyl-6,2'-bis-(2-methoxy-ethoxymethoxy)-biphenyl-3-yl]-succinic acid dimethyl ester 
• 488713-67-3 2-[3-formyl-4-(2-methoxy-ethoxymethoxy)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxa-borolan-2-yl)-phenyl]-succinic acid dimethyl ester 
• 878673-54-2 2-[3-bromo-5-formyl-4-(2-methoxy-ethoxymethoxy)-phenyl]-succinic acid dimethyl ester 
• 488713-18-4 2-(3-bromo-5-formyl-4-hydroxy-phenyl)-succinic acid dimethyl ester 
• 488713-20-8 2-(3-formyl-4-hydroxy-phenyl)-succinic acid dimethyl ester 

Relevant articles and documents

Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model

Highly selective and potent factor VIIa-tissue factor (fVIIa · TF) complex inhibitors were generated through structure-based design. The pharmacokinetic properties of an optimized analog (9) were characterized in several preclinical species, demonstrating